Business Description
Advaxis Inc
NAICS : 325414
SIC : 2834
ISIN : US0076242082
Description
Advaxis Inc is a clinical-stage biotechnology company operating in the United States. It focuses on the discovery, development, and commercialization of proprietary Lm (Listeria monocytogenes)-LLO (Listeriolysin O) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. The company's immunotherapy products based on Lm-LLO immunotherapy are Axalimogene filolisbac (AXAL) which targets Human Papilloma Virus (HPV) - associated cancers and ADXS-PSA which targets Prostate-Specific Antigen (PSA) associated with prostate cancer.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 10.13 | |||||
| Equity-to-Asset | 0.46 | |||||
| Debt-to-Equity | 0.17 | |||||
| Debt-to-EBITDA | -0.07 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 1/9 | |||||
| Altman Z-Score | -13.8 | |||||
| Beneish M-Score | -5.81 | |||||
| WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -89.2 | |||||
| 3-Year EBITDA Growth Rate | 53.4 | |||||
| 3-Year EPS without NRI Growth Rate | 54.1 | |||||
| 3-Year FCF Growth Rate | 64.9 | |||||
| 3-Year Book Growth Rate | -40.9 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 40.67 | |||||
| 9-Day RSI | 42.31 | |||||
| 14-Day RSI | 43.43 | |||||
| 6-1 Month Momentum % | -23.9 | |||||
| 12-1 Month Momentum % | -76.7 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.86 | |||||
| Quick Ratio | 1.86 | |||||
| Cash Ratio | 1.71 | |||||
| Days Sales Outstanding | 5.75 | |||||
| Days Payable | 167010.31 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -42.5 | |||||
| Shareholder Yield % | -730.82 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 98.43 | |||||
| Operating Margin % | -9433.86 | |||||
| Net Margin % | -8407.48 | |||||
| FCF Margin % | -7304.24 | |||||
| ROE % | -88.38 | |||||
| ROA % | -74.57 | |||||
| ROIC % | -1027.28 | |||||
| ROC (Joel Greenblatt) % | -3625.11 | |||||
| ROCE % | -97.67 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 4.35 | |||||
| PB Ratio | 0.3 | |||||
| Price-to-Tangible-Book | 0.44 | |||||
| EV-to-EBIT | 0.44 | |||||
| EV-to-EBITDA | 0.45 | |||||
| EV-to-Revenue | -41.65 | |||||
| EV-to-FCF | 0.59 | |||||
| Price-to-Net-Current-Asset-Value | 0.61 | |||||
| Price-to-Net-Cash | 0.77 | |||||
| Earnings Yield (Greenblatt) % | 227.27 | |||||
| FCF Yield % | -621.51 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Advaxis Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.236 | ||
| EPS (TTM) (€) | -9.652 | ||
| Beta | 0 | ||
| Volatility % | 95.49 | ||
| 14-Day RSI | 43.43 | ||
| 14-Day ATR (€) | 0.111618 | ||
| 20-Day SMA (€) | 0.935 | ||
| 12-1 Month Momentum % | -76.7 | ||
| 52-Week Range (€) | 0.535 - 4.0545 | ||
| Shares Outstanding (Mil) | 4.84 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Advaxis Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Advaxis Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Advaxis Inc Frequently Asked Questions
What is Advaxis Inc(STU:FAD)'s stock price today?
The current price of STU:FAD is €0.77. The 52 week high of STU:FAD is €4.05 and 52 week low is €0.54.
When is next earnings date of Advaxis Inc(STU:FAD)?
The next earnings date of Advaxis Inc(STU:FAD) is .
Does Advaxis Inc(STU:FAD) pay dividends? If so, how much?
Advaxis Inc(STU:FAD) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers